<DOC>
	<DOCNO>NCT02181803</DOCNO>
	<brief_summary>This 3-part dose titration study ass MK-8189 safety , tolerability , pharmacokinetics ( PK ) , central nervous system activity . Part 1 assess MK-8189 administer monotherapy participant schizophrenia . Part 2 assess MK-8189 administer add-on atypical antipsychotic treatment participant schizophrenia . Part 3 assess monotherapy MK-8189 healthy participant , include Japanese descent . The primary hypothesis least one dose MK-8189 generally safe well-tolerated desire PK parameter participant schizophrenia .</brief_summary>
	<brief_title>MK-8189 Multiple Dose Study Healthy Volunteers Schizophrenia Patients ( MK-8189-003 )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>INCLUSION CRITERIA FOR SCHIZOPHRENIA PARTICIPANTS Male nonpregnant nonbreast feed female . If participant male female partner childbearing potential , participant must agree use medically acceptable method contraception trial 120 day last dose trial drug . If partner pregnant , male must agree use condom Body Mass Index ( BMI ) ≥ 18.5 ≤ 40 kg/m^2 Meet diagnostic criterion schizophrenia schizoaffective disorder accord Diagnostic Statistical Manual Mental Disorders ( DSM ) criterion onset first episode le 2 year prior study entry Be nonacute phase illness clinically stable 3 month prior screen History receive tolerate antipsychotic medication within usual dose range employ schizophrenia Participants hypothyroidism , diabetes , high blood pressure , chronic respiratory condition mild form medical condition could consider candidate study enrollment condition stable prescribe dose regimen medication stable least 3 month prior screen expect change comedication study Has negative urinary drug screen screen INCLUSION CRITERIA FOR HEALTHY PARTICIPANTS Male , nonpregnant nonbreast feed female Japanese nonJapanese descent . If participant male female partner childbearing potential , participant must agree use medically acceptable method contraception trial 120 day last dose trial drug . If partner pregnant , male must agree use condom Body Mass Index ( BMI ) ≥ 18.5 ≤ 35 kg/m^2 In good health Nonsmoker and/or use nicotine nicotinecontaining product ( e.g. , nicotine patch ) least approximately 3 month Has negative urinary drug screen screen EXCLUSION CRITERIA FOR SCHIZOPHRENIA PARTICIPANTS DSMIV axis I psychiatric diagnosis schizophrenia schizoaffective disorder within one month screening Has evidence history mental retardation , borderline personality disorder , anxiety disorder , organic brain syndrome History neuroleptic malignant syndrome moderate severe tardive dyskinesia Untreated uncompensated clinically significant renal , endocrine , hepatic , respiratory , gastrointestinal , psychiatric , neurologic , cardiovascular , hematological , immunological cerebrovascular disease , malignance , allergic disease chronic and/or degenerative process screening Has history cancer ( malignancy ) certain exception Treatment clozapine schizophrenia treatment monoamine oxidase inhibitor within 3 month screen Received parenteral depot antipsychotic medication within 3 month screen Participated another investigational study within 4 week , prior screen EXCLUSION CRITERIA FOR HEALTHY PARTICIPANTS History clinically significant endocrine , gastrointestinal , cardiovascular ( include hypertension , angina , coronary artery disease , valvular disease , heart rate rhythm abnormality ) , hematological , hepatic , immunological , renal , respiratory , genitourinary major neurological ( include stroke chronic seizure ) abnormality diseases Mentally legally incapacitate History clinically diagnose depression , anxiety disorder , history psychiatric disorder require drug treatment hospitalization History cancer ( malignancy ) Unable refrain anticipates use medication , include prescription nonprescription drug herbal remedy throughout trial Participated another investigational study within 4 week , prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>